RPAY Jumps As KUBRA Deal Ignites Activist Showdown

Repay Holdings Corporation stocks have been trading up by 27.52 percent following upbeat earnings guidance and strong transaction volume growth.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading RPAY

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Repay Holdings plans to buy KUBRA for about $372M in cash, funded with cash and a new $500M term loan, aiming for scale in bill payments and customer communications plus material cost synergies.
Activist Veradace Partners, holding 8.4%, is pushing RPAY’s board to scrap the KUBRA deal and add two shareholder-backed directors after a sharp post-deal share drop.
RPAY has doubled down on completing the KUBRA acquisition, highlighting recurring, non‑discretionary payment flows and deeper enterprise ties, with no shareholder vote required.
The company adopted a limited‑duration poison pill through 2027, capping ownership near 12.5% to deter hostile control grabs while preserving a path for fully financed, all‑cash bids.
RPAY also named payments veteran Matt Morrow to lead Consumer Payments, strengthening its bench as it pursues scale and integration.

Live Update At 10:02:39 EDT: On Friday, April 17, 2026 Repay Holdings Corporation stock [NASDAQ: RPAY] is trending up by 27.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RPAY has quietly turned into a battleground stock, but the numbers show why traders keep coming back to this chart. Over the last few weeks, Repay Holdings has ripped from roughly $2.60 at the end of March to about $4.06 on 2026/04/17. That is a big percentage move for a low‑priced name, and it tells you momentum traders are in control.

Look at the daily candles: RPAY based in the high‑$2s and low‑$3s, then broke out above $3.10 and never really looked back. On 2026/04/17, the intraday action shows a wild premarket spike from the low‑$3s up toward $4.80 before fading and stabilizing around $4.00–$4.15. That kind of range is catnip for short‑term trading.

More Breaking News

Fundamentals are messy. RPAY posts strong gross margins around 75%, but bottom‑line margins are deeply negative and returns on equity and assets sit in the red. At the same time, the stock trades at less than 1x sales and around 0.6x book, with a low price‑to‑cash‑flow. Debt is meaningful, with total‑debt‑to‑equity near 0.9 and a current ratio under 1, so leverage and liquidity matter. For active traders, RPAY is a classic story: cheap on some metrics, bruised on earnings, and now throwing off big volatility.

Why Traders Are Watching RPAY’s KUBRA Drama

RPAY is in the spotlight because Repay Holdings is swinging for scale with the KUBRA Data Transfer deal while an activist tries to block the shot. The company agreed to buy KUBRA for about $372M in cash, funded through existing cash and a new $500M term loan. Management is pitching a bigger, vertically focused bill‑pay and customer communication platform spanning utilities, government, and insurance.

If RPAY hits its own targets, the combined business could reach roughly $548M of revenue and about $178M of adjusted EBITDA in 2025, with more than $20M of annual cost and technology synergies over three years and stronger free cash flow by 2028. That is the bull case: more scale, richer margins, and a portfolio of sticky, non‑discretionary payment flows.

Wall Street is not unified, but at least one shop is leaning in. DA Davidson called the KUBRA acquisition “sizable” and “strategically important,” and it stuck with a Buy rating and an $8 price target on RPAY despite higher leverage and integration risk. For swing traders, that sets a clear upside reference point versus today’s $4‑ish tape.

On the other side sits Veradace Partners, an 8.4% holder. Veradace is publicly demanding the board terminate the KUBRA deal, citing RPAY’s sharp drop and underperformance after the announcement. It also wants two shareholder representatives on the board to investigate the transaction and oversee capital allocation. Management fired back by reaffirming its commitment to the acquisition and reminding the market that the transaction is fully papered and does not require a shareholder vote.

Layer in a stockholder rights plan and you have real drama. RPAY adopted a limited‑duration poison pill through 2027 that effectively caps any holder around 12.5% without paying a control premium. The plan still allows a fully financed, all‑cash bidder to force a vote under a qualifying‑offer feature. Interestingly, RPAY traded about 2% higher in premarket trading after the pill news, signaling that at least some traders see value in blocking any stealth control grab while the KUBRA debate plays out.

Meanwhile, Repay Holdings added Matt Morrow, a veteran from Xplor Technologies and TSYS, to lead Consumer Payments. For traders, that signals RPAY is not just talking about scale; it is bringing in leadership to actually run it. Put together, the story is simple: a leveraged acquisition, a loud activist, defensive tactics from the board, and a chart waking up. That is why RPAY sits on so many watchlists right now.

Conclusion

RPAY is now a real‑time case study in how strategy, governance, and trading all collide. Repay Holdings wants KUBRA because it promises bigger scale, more recurring bill‑pay volume, and a clearer path to stronger free cash flow by 2028. An analyst price target at $8 shows some on the Street are willing to underwrite that vision even as leverage climbs.

At the same time, Veradace’s public campaign against the deal, plus RPAY’s poison pill, tells traders this story is far from settled. A rights plan that runs to 2027 and caps ownership near 12.5% is a clear message: the board intends to control the timing and terms of any change in control while it pushes the KUBRA integration forward. That can reduce the odds of a quick hostile bid, but it keeps the activist narrative front and center.

For short‑term traders, RPAY’s recent move from the high‑$2s into the low‑$4s, with big intraday swings, is the main attraction. The catalyst deck is loaded: regulatory approvals for KUBRA, any change in Veradace’s stance, possible tweaks to the deal, and execution updates from the new Consumer Payments head. As Tim Sykes likes to say, “The market rewards prepared traders, not hopeful ones.” In the same vein, and especially in a volatile setup like RPAY, clarity of your trading thesis is critical; as Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.”. With RPAY, that means tracking every filing, headline, and chart shift and being ready to act fast, cut losses even faster, and treat this setup purely as an educational and research opportunity—not a substitute for your own due diligence.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!